Oncolytic adenoviral vectors are currently being developed as biologic anticancer agents. Coupling the lytic function of an oncolytic adenovirus (Ad) with its ability as a transgene delivery system represents a powerful extension of this methodology. A clear advantage is the amplification of a therapeutic gene, as replicating vectors would be able to infect and deliver the gene of interest to neighboring cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of the most potent stimulators of a specific and long-lasting antitumor immunity and its important role in the maturation of antigen-presenting cells to induce T-cell activation has been well documented. Similarly, the B7 family has also been shown to play an integral role in mediating an antitumor response. Most tumor cells, however, lack the expression of these costimulatory molecules on their surface, thus escaping immune system recognition. To increase the antitumor effect of an oncolytic Ad, we have generated an E1B 55 kDa-deleted oncolytic adenoviral vector, YKL-GB, that expresses both GM-CSF and B7-1. The therapeutic efficacy of YKL-GB Ad was evaluated in immunocompetent mice bearing murine melanoma B16-F10 tumors. Significant inhibition of tumor growth was seen in mice treated with YKL-GB compared to those treated with the analogous vector, YKL-1. Moreover, YKL-GB oncolytic Ad demonstrated enhanced antitumor activity and higher incidences of tumor regression compared to a replication-incompetent Ad, dl-GB, which coexpresses GM-CSF and B7-1. Localized GM-CSF and B7-1 gene transfer also conferred long-lasting immunity against a tumor re-challenge. To establish that the observed antitumor effect is associated with the generation of a tumorspecific immune response, we carried out interferon-g enzymelinked immune spot assay. We observed that YKL-GB induced significantly higher immune cell activation than YKL-1. Furthermore, immunohistochemical studies demonstrated robust dendritic cells and CD4 + /CD8 + T-cell infiltration in these mice compared to the YKL-1-treated groups. In agreement with these results, splenocytes from tumor-bearing mice treated with YKL-GB expressed high levels of the costimulatory and activation molecules. These findings demonstrate the effectiveness of enhancing the immune response against tumors with an oncolytic Ad expressing both GM-CSF and B7-1 and provide a potential therapeutic strategy for the management of neoplasia.
Introduction
Cancer immunotherapy has seen revived interest as different types of immune cells and cancer-specific surface antigens that induce an immune response are rapidly being discovered. Several cytokines, including interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), B7-1, IL-12, interferon (IFN)-a and IFN-g, have demonstrated significant antitumor effects. Among these, GM-CSF is one of the most potent, specific and long-lasting inducers of antitumor systemic immunity.
1,2 Granulocyte-macrophage colony-stimulating factor mediates its effect by stimulating the differentiation and activation of antigen-presenting cells (APC), namely dendritic cells (DC) and macrophages. 3, 4 The APCs in turn, process and present tumor antigens to helper T cells and CTL cells, augmenting the immune response. 5, 6 As such, GM-CSF is particularly effective in generating systemic immunity against a number of poorly immunogenic tumors. [7] [8] [9] In addition to antigen presentation, successful cancer immunotherapy requires the engagement of the T-cell receptor with an antigen/major histocompatibility complex and a costimulatory molecule such as B7-1 (CD80) and B7-2 (CD86). [10] [11] [12] Unfortunately, however, most tumor cells lack the B7 family, 13, 14 and thus exhibit T-cell tolerance. One approach to overcome this unresponsiveness or T-cell tolerance is to activate and recruit DCs. 15 In this strategy, a combination of B7 costimulation and overproduction of GM-CSF may be beneficial, as each promote one of two main routes by which cytotoxic T-cell activation occursdirect antigen presentation and cross-priming by professional APCs. 16, 17 Recent studies have shown that increased local production of GM-CSF or B7 gene family by genetically modified tumor cells can induce specific antitumor cellular immunity in vitro and in vivo. 10 Furthermore, GM-CSF has been shown to actively recruit DC in vivo. 6, 18, 19 However, the therapeutic efficacy of cytokine gene transfer by replication-incompetent vector has often met disappointing results, especially in pre-established tumors.
Oncolytic adenoviruses (Ads) are currently undergoing evaluation as biologic anticancer agents in human clinical trials. [20] [21] [22] This treatment takes advantage of the lytic nature of a viral infection to eradicate the tumor mass in a cancer cell-specific manner. Coupling the lytic function of an oncolytic Ad with virus-mediated transgene delivery represents a powerful extension of this modality. A clear benefit is the amplification effect in which the replicating vector would be able to infect and deliver the therapeutic gene to neighboring cancer cells, ultimately enhancing the potential of the virus-based therapy to deal with the complexity of a human tumor.
The present study examined the immunotherapeutic potency of GM-CSF and B7-1 coexpression combined with oncolytic Ad against an established B16-F10 melanoma model. We also examined the effector cell responses that mediate the antitumor effect, as well as the maturation of DCs in a tumor mass to determine the mechanism of action by which this combination therapy exerts its antitumor effects. Moreover, we describe the synergistic oncolytic ability of combination therapy using cytokineexpressing oncolytic Ad, potentiating its antitumor effect.
Results
Adenovirus-mediated granulocyte-macrophage colony-stimulating factor and B7-1 expression
To express both GM-CSF and B7-1 in a single Ad vector, two independent expression cassettes, one for expressing murine GM-CSF and the other for murine B7-1, were placed in E1 and E3 region of a replication-incompetent Ad and replication-competent Ad, generating dl-GB and YKL-GB, respectively ( Figure 1 ). The expression level of GM-CSF and B7-1 derived from these two constructed Ads was then compared. B16-F10 cells were infected with dl-GB or YKL-GB at different multiplicities of infection (MOIs) and GM-CSF expression was measured in the culture medium at 48 h post-infection using a conventional enzyme-linked immunosorbent assay (ELI-SA) kit. As seen in Figure 2a , GM-CSF expression levels increased linearly up to 100 MOI. More specifically, the GM-CSF expression levels by YKL-GB infection at an MOI of 10, 20, 50 and 100 were 41 450, 123 200, 390 800 and 474 800 pg/ml, respectively, whereas those by dl-GB were 298, 505, 3013 and 37 240 pg/ml, indicating that YKL-GB induced markedly elevated GM-CSF expression levels compared to those of dl-GB at all MOIs examined.
The expression level of B7-1 was assessed by flow cytometric analysis 48 h after infection with dl-GB or YKL-GB in B16-F10 cells. The B7-1 expression level was also directly proportional to the MOIs used for infection (Figure 2b ). At an MOI of 10, 50, 100 and 500, the mean fluorescence intensities (MFI) of dl-GB infection were 1.42, 1.81, 2.24 and 12.17, whereas those of YKL-GB were 159.29, 627.08, 886.73 and 1243.12, indicating significantly higher expression of B7-1 in YKL-GB-infected cells. Consistent with GM-CSF expression results, the expression of B7-1 observed at an MOI of 100 and 500 by YKL-GB Ad infection was approximately 400-and 100-fold higher than that with dl-GB Ad-mediated gene transfer. Taken together, these results demonstrate significantly higher expression levels of both GM-CSF and B7-1 by replication-competent YKL-GB Ad in contrast to the replication-incompetent dl-GB Ad. Figure 1 Schematic representation of adenovirus (Ad) vectors used in this study. dl-LacZ comprises of the b-galactosidase gene inserted into the E1 region of E1-deleted replication-incompetent Ad. Ad-XC has the same backbone as wild-type Ad except for the deletion of the E3 region; dl-LacZ is comprised of the b-gal gene under the constitutive control of the CMV promoter inserted into the E1 region; dl-GB is an E1-deleted replication-incompetent Ad with granulocyte-macrophage colony-stimulating factor (GM-CSF) and B7-1 genes driven by the CMV promoter inserted into the E1 and E3 region, respectively; YKL-1 contains normal E1A and E1B 19 kDa, but lacks E1B 55 kDa; YKL-GB is comprised of the GM-CSF and B7-1 genes driven by the CMV promoter inserted into the E1 and E3 regions of YKL-1, respectively. DE3 denotes the deletion of E3 6.7K, gp19K, ADP, 10.4K, 14.5K and 14.7K genes.
YKL-GB
Oncolytic adenovirus-expressing GM-CSF and B7-1
Granulocyte-macrophage colony-stimulating factor and B7-1 expression does not inhibit viral replication
To determine whether expression of GM-CSF and B7-1 would alter viral replication, the newly engineered Ads were examined for their potential to induce cytopathic effects (CPE) in multiple cell lines. Because human cells are highly permissive to adenoviral replication, in addition to the murine melanoma cell line (B16-F10), we employed six different types of human cancer cell lines (H460, A549, Hep1, HeLa, U251N, U343) from varying histological types. Various cell lines were infected with YKL-1 (cognate oncolytic Ad) or YKL-GB Ad at MOIs of 1, 5, 10, 50 and 100, in which the subjected cells were treated with crystal violet to show the relative extent of cell lysis. For negative and positive controls, cells were infected in parallel with replication-incompetent Ad, dl-LacZ, and wild-type Ad, Ad-XC, respectively. As seen in Figure 3 , virally induced CPE appeared to be same or slightly faster in YKL-GB as compared to YKL-1. This result was consistent over several independent experiments, suggesting that GM-CSF and B7-1 expression does not inhibit viral replication.
Antitumor effects of granulocyte-macrophage colonystimulating factor-and B7-1-expressing adenoviruses
To determine the antitumor effect of locally delivered oncolytic Ad coexpressing GM-CSF and B7-1, immunocompetent mice bearing the B16-F10 melanoma were treated with direct intratumoral administration of phosphate-buffered saline (PBS), dl-GB, YKL-1 or YKL-GB. As seen in Figure 4a , control tumors treated with PBS increased significantly to an average tumor size of 34047669 mm 3 by 11 days after initial injection. In comparison, the average tumor size of mice treated with GM-CSF and B7-1 coexpressing Ads, dl-GB and YKL-GB, were 1947128 and 35712 mm 3 , respectively, demon- Oncolytic adenovirus-expressing GM-CSF and B7-1 K-J Choi et al strating significant tumor growth suppression. However, the average tumor size of mice treated with YKL-1 at 11 days after infection was 8437220 mm 3 , showing reduced tumor growth suppression compared to Ads expressing GM-CSF and B7-1. By day 17 post-treatment, dl-GBtreated tumors showed signs of re-growth but YKL-GBtreated tumors continued to exhibit tumor stasis. The tumor volume at day 17 post-treatment for viral-treated tumors was 4937241 and 51740 mm 3 for dl-GB and YKL-GB, respectively. Furthermore, the mice survival rate was significantly enhanced by the treatment with YKL-GB (Po0.005 versus PBS; Po0.005 versus YKL-1; Po0.05 versus dl-GB) ( Figure 4b ). Mean survival of YKL-GB-treated mice was more than twofold than that of PBStreated control mice group. Of the two Ads expressing GM-CSF and B7-1, YKL-GB was chosen for the following functional studies as YKL-GB demonstrated substantially greater antitumor effect than dl-GB.
In vivo YKL-GB-infected B16-F10 cells produce high amounts of granulocyte-macrophage colonystimulating factor and interferon-g
We next analyzed tumor cells for their production of GM-CSF and IFN-g in vivo. At 3 days after fifth viral injection, tumor tissues were removed and intratumoral cytokines were determined using an ELISA as described in Materials and methods. (4) at various multiplicities of infection, and cell killing was allowed to proceed for about 6-10 days, followed by crystal violet staining to detect live cells. Replication-incompetent dl-LacZ and Ad-XC served as a negative and a positive control, respectively. The experiment was performed three times, and the representative results are shown. The expression of granulocyte-macrophage colony-stimulating factor and B7-1 did not compromise the virus's ability to induce classical CPE. To evaluate DC population, which are known to be the most potent APCs, splenocytes were also analyzed for their expression of CD11b, CD80 and CD86 by flow cytometry. Analysis of these results from three to five independent experiments revealed that the YKL-GBtreated splenocytes expressed increased level of activation/costimulatory molecules when compared to PBS-or YKL-1 treated splenocytes (Figure 5d ). Our data showed that the MFI levels were higher for the YKL-GB-treated splenocytes (CD11b (1856. Oncolytic adenovirus-expressing GM-CSF and B7-1 K-J Choi et al
Interferon-g enzyme-linked immune spot assay
To determine whether coexpression of GM-CSF and B7-1 could enhance tumor-specific immune responses in mice, number of cells expressing IFN-g, a cytokine secreted by CTL, was evaluated through IFN-g enzyme-linked immune spot (ELISPOT) assay. Adenovirus-infected animals were killed on day 3 post-final viral injection and their spleens were harvested. The serially diluted splenocytes from 1 Â 10 5 to 1 Â 10 6 cells per well were then added to the anti-IFN-g antibody-coated 96-well plate, and the number of IFN-g-secreting cells was subsequently assessed. As presented in Figure 6 , minimal detectable reactivity was observed in splenocytes from PBS-treated mice, whereas significant reactivity was observed in YKL-1-or YKL-GB-treated mice. In particular, the frequency of IFN-g-secreting immune cells recovered from mice injected with YKL-GB was significantly greater than that rescued from mice given YKL-1 (Figure 6b ), revealing that animals treated with YKL-GB generated higher immune cell activation than those treated with YKL-1.
Increased lymphocyte and dendritic cell infiltration in YKL-GB adenovirus-treated tumor tissue
Histological analysis with hematoxylin and eosin (H&E) staining was carried out to study lymphocyte infiltration into tumor tissues. As seen in Figure 7 , mild infiltration was observed around the tumor tissue treated only once with YKL-1 or YKL-GB, whereas in groups treated with PBS, there was extensive central necrosis, but no lymphocytic infiltration was observed. A peripheral rim pattern of lymphocytic infiltration was observed in the tumor sections from mice treated three times with YKL-1 or YKL-GB. In particular, for tumors treated three or five times with YKL-GB, comparatively extensive lymphocytic infiltration intermingled with nuclear debris was observed not only around but inside the tumor tissue as well. Moreover, in the YKL-GB-treated group, almost all of the remaining tumor tissue appeared to be necrotic.
In order to identify the cells recruited into the tumor bed, tumor sections were analyzed by immunohistochemistry using anti-CD4 or anti-CD8 monoclonal antibodies. The results from tumors analyzed at day 11 after viral injection are presented in Figure 8a . The predominant cell type found in all infiltrates after injection with adenoviral vector was a population of In particular, the number of both CD4 + and CD8 + cells was substantially higher in sections derived from YKL-GB-treated animals compared to PBS-or YKL-1-treated animals. To further examine whether coexpression of GM-CSF and B7-1 stimulates the recruitment of DCs in situ, the presence of DCs in the tumor tissues was analyzed. As shown in Figure 8b , more abundant CD86 + -stained cells with dendritic morphology were observed in the tumor tissues treated with YKL-GB when compared with control vector, YKL-1, indicating that a higher number of CD86 + DCs were recruited to the tumor in mice treated with YKL-GB.
Viral replication and persistence within the tumor mass was then confirmed by immunohistochemistry using an antibody specific to adenoviral hexon protein.
Clusters of adenoviral particles were detected in wide areas of YKL-1-or YKL-GB-treated tumors, most frequently in the peripheral tumor area and in between the areas of necrosis and proliferating tumor cells, whereas no adenoviral particles were detected in the PBS-treated tumors (Figure 8c ).
Generation of systemic immunity
To determine the establishment of systemic immunity, mice that were tumor free for at least 3 months after the Oncolytic adenovirus-expressing GM-CSF and B7-1 K-J Choi et al end of YKL-GB treatment of B16-F10 tumors were re-challenged with 5 Â 10 5 B16-F10 cells on day 90 after the initial virus administration, and their survival was evaluated. None of the re-challenged mice developed tumors, and all remained tumor free for an additional 60 days after the challenge. To ensure the tumor-forming capacity of these cells, untreated age-matched syngeneic mice were included to observe the kinetics of tumor growth.
Discussion
Dendritic cells are an attractive target to use as an inducer of tumor immunity because of their critical importance in generating a CD4 + and CD8 + T-cellspecific cytolytic immune response. [24] [25] [26] [27] In addition, because of their unique ability to act as a biological adjuvant, DCs are receiving increased attention in immunotherapy research. Granulocyte-macrophage colony-stimulating factor has been suggested to be essential for regulating survival, proliferation, differentiation and function of DCs both in human and murine systems. 7, 28, 29 Recently, Pan et al. 6 showed that APCs like DCs were recruited and became mature by intratumor gene delivery of GM-CSF. The expression of B7 gene family has also been shown to be an important mechanism for antitumor responses in both mice and humans. [30] [31] [32] However, most tumor cells lack expression of these costimulatory molecules on their surface, thus escaping from recognition by the immune system. Accordingly, to improve the tumor cells' immunogenicity, we have engineered Ads to express both GM-CSF and B7-1 as immunomodulatory genes to be utilized in cancer gene therapy. In addition, in an effort to augment the efficiency of antitumor effect elicited by the combination of gene therapy using GM-CSF and B7-1, we chose E1B 55 kDa-deleted oncolytic Ad (YKL-1) as a vector to drive coexpression of GM-CSF and B7-1. The rationale for this design is based on the fact that active replication of oncolytic Ad in tumor tissue should cause tumor cell death and the release of tumor antigens in situ. Subsequently, the released antigens should be captured by GM-CSF-recruited APCs, and in concert with B7-1, activate tumor-specific T cells, ultimately leading to the eradication of tumors and the generation of persistent antitumor responses in mice treated with the combination virotherapy.
The expression level of GM-CSF and B7-1 induced by dl-GB and YKL-GB was first examined in B16-F10 cells. As demonstrated in Figure 2 , expression levels of both GM-CSF and B7-1 by replication-competent YKL-GB were significantly higher than those by replicationincompetent dl-GB. For example, YKL-GB-driven GM-CSF and B7-1 expression was markedly increased by 12-and 395-fold (at an MOI of 100), respectively, in comparison to those by dl-GB. These results indicate that in addition to delivery of the therapeutic genes to adjacent cells, the YKL-GB would be able to replicate and express GM-CSF and B7-1 in strikingly elevated levels, which ultimately would result in the amplification of the expression levels of GM-CSF and B7-1 genes. However, the expression of GM-CSF and B7-1 in vitro from the replicating Ad did not compromise the viral ability to induce classical CPE in infected cells or abolish the ability of the virus to produce viral progenies (Figure 3) .
The therapeutic efficacy of dl-GB or YKL-GB Ad was then evaluated in immunocompetent mice bearing murine melanoma B16-F10 tumors. Significant inhibition of tumor growth was shown in mice treated with Ads expressing GM-CSF and B7-1 (dl-GB and YKL-GB). Moreover, YKL-GB oncolytic Ad demonstrated enhanced antitumor effect and a higher incidence of complete tumor regression compared to the analogous vector, YKL-1 or dl-GB. Survival rate was also significantly prolonged in the YKL-GB-treated mice. Taken together, these results suggest that the combination of using oncolytic Ad along with overexpression of GM-CSF and B7-1 elicits more potent antitumor effect than either YKL-1 or dl-GB.
In tumor-bearing mice treated with YKL-GB gene therapy, significantly higher levels of GM-CSF and IFN-g were detected in the tumor when compared with PBStreated tumor-bearing mice or those treated with YKL-1. Localized GM-CSF and B7-1 gene transfer also conferred long-lasting immunity against tumor re-challenge. All mice that had undergone complete regression for 3 months following initial treatment with YKL-GB resisted a second challenge with the same tumor cell line, B16-F10. This demonstrates that mice once treated with GM-CSF and B7-1 gene therapy develop long-term tumor-specific immunity. Furthermore, splenocytes from tumor-bearing mice expressed high levels of costimulatory and activation molecules and the YKL-GB infection induced further DC maturation (Figure 5d ). In agreement with these results, previous reports have demonstrated that Ad vectors expressing GM-CSF induced maturation of DC and that this effect was associated with NF-kB activation. 6, 33, 34 In order to establish that the generation of tumorspecific immune response was responsible for the observed antitumor effect, we carried out IFN-g ELISPOT assay. We observed that YKL-GB induced significantly higher immune cell activation than YKL-1. The histological and immunohistochemical studies also showed a massive infiltration of DCs and CD4 + /CD8 + T cells into the tissues surrounding the necrotic tumor area after in situ delivery of Ad-expressing GM-CSF and B7-1. These findings imply that the presence of GM-CSF at the site of the tumor both attracts DC from surrounding tissues and promotes their maturation from hematopoietic precursors, both of which should enhance the induction of specific antitumor immune responses. These data are consistent with the observations of Mach et al., 19 who demonstrated that large numbers of DCs localize at the site of inoculation with GM-CSF-transfected melanoma cells. In addition, the expression of B7-1 should make tumor cells more competent in directing antigen presentation to T cells, ultimately enhancing the activation of T cells.
In conclusion, the findings of this study demonstrate the effectiveness of augmenting the immune response against tumors with oncolytic Ad expressing both GM-CSF and B7-1. The YKL-GB Ad showed augmented and prolonged effect in suppressing tumor growth in vivo, in contrast to the YKL-1 Ad that showed only limited and temporary antitumor effect. Moreover, the dl-GB Ad, despite being replication incompetent, showed higher efficacy in suppressing tumor growth compared to the YKL-1 Ad. However, the therapeutic advantage of treatment with oncolytic Ad such as YKL-1 or YKL-GB Oncolytic adenovirus-expressing GM-CSF and B7-1 K-J Choi et al would be greatly enhanced in human system because human tumor cells are much more permissive to adenoviral infection and replication. As the therapeutic value of YKL-GB Ad has been verified to be very high, further studies are being planned to investigate the application of this Ad for cancer therapy, especially in preventing metastasis and secondary tumorigenesis. Overall, given the results shown in this study, oncolytic Ad-mediated GM-CSF and B7-1 gene transfer may provide a new paradigm as a potential therapeutic strategy in combating cancer.
Materials and methods

Cell culture
The 293 cell line (adenoviral E1-transformed human embryonic kidney cells) was maintained in Dulbecco's modified Eagle's medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS; Gibco BRL). B16-F10 cells (Seoul National University Cell Bank, Seoul, Korea) were grown in RPMI (Gibco BRL) plus 10% FCS. All cell culture media were supplemented with 2 mM L-glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin.
Generation of adenoviruses-expressing granulocytemacrophage colony-stimulating factor and B7-1
To generate an Ad expressing GM-CSF and B7-1 at the E1 and E3 region, respectively, we first constructed an E3 shuttle vector expressing B7-1. The murine B7-1 gene was excised from pLNCX-B7-1 using BstBI and ClaI, and subcloned into the Ad E3 shuttle vector, pSP72-E3, 35 generating a pSP72-B7-1. The newly constructed pSP72-B7-1 shuttle vector was linearized with XmnI digestion, and then co-transformed with a replication-incompetent Ad total vector, vmdl324Bst (SB Verca, University of Fribourg, Switzerland) into Escherichia coli BJ5183. It was then digested with SpeI for homologous recombination, yielding Ad plasmid, pdl-B7.1. Structures of the resultant recombinant vectors were then confirmed by restriction enzyme digestion and PCR analysis. To construct an Ad E1 shuttle vector expressing GM-CSF, a murine GM-CSF gene was excised from pCDNA3.1-GMCSF (ATCC, Rockville, MD, USA) using HindIII and EcoRI, and subcloned into the replication-incompetent E1 shuttle vector, pCA14 vector (Microbix, Ontario, Canada), and E1B 55 kDa-deleted replication-competent E1 shuttle vector, pCA14-DE1B55, 36 resulting in pCA14-GMCSF and pCA14-DE1B55-GMCSF Ad E1 shuttle vectors, respectively. Then, these Ad E1 shuttle vectors were linearized with BstBI digestion, and co-transformed into E. coli BJ5183 with the ScaI-digested pdl-B7-1 for homologous recombination, generating pdl-GB and pYKL-GB, respectively. The proper recombinant adenoviral plasmid was digested with PacI and transfected into 293 cells generating the replication-incompetent Ad, dl-GB, and oncolytic Ad, YKL-GB (Figure 1 ). E1-deleted replication-incompetent Ad encoding the bacterial LacZ gene (dl-LacZ), E1B 55 kDa-deleted oncolytic Ad (YKL-1), and wild-type Ad (Ad-XC) were also prepared ( Figure 1 ). All viruses were propagated in 293 cells, purified by CsCl density purification, dissolved in storage buffer (10 mM Tris, 4% sucrose, 2 mM MgCl 2 ) and stored at À801C. Viral particle (v.p.) numbers were calculated from measurements of optical density at 260 nm (OD 260 ), where 1 absorbency unit is equivalent to 10 12 v.p. per milliliter, and infectious titers (plaqueforming units (PFU) per milliliter) were determined by limiting dilution assay on 293 cells; the MOI was calculated from infectious titers.
Enzyme-linked immunosorbent assay for granulocytemacrophage colony-stimulating factor expression B16-F10 murine melanoma cells (5 Â 10 5 ) were infected with dl-GB or YKL-GB at different MOIs in 25-T culture flasks. Forty-eight hours later, the supernatant was collected and tested for GM-CSF by ELISA (Endogen, Woburn, MA, USA). Serial dilutions of a known concentration of purified recombinant mouse GM-CSF were used to establish a standard curves.
Fluorescence-activated cell sorting analysis for B7-1 expression
The expression level of B7-1 was analyzed after incubating the cells with dl-GB or YKL-GB at different MOIs in T-25 culture flasks. At 48 h after infection, cells were raised with cell dissociation solution (Sigma, St Louis, MO, USA), and washed with PBS. Phycoerythrin (PE)-conjugated hamster anti-mouse CD80 monoclonal antibody (Pharmingen, San Diego, CA, USA) was subsequently added at 41C for 45 min. After PBS washing, 500 ml of PBS was added to perform flow cytometric analysis. Cells were analyzed on a FACScan (BecktonDickinson, Sunnyvale, CA, USA), using CellQuest software (Beckton-Dickinson).
Cytopathic effect assay
In order to assess whether virally expressed GM-CSF and B7-1 altered the Ad's ability to replicate, CPE values, which directly correlate to the degree of viral replication, of the samples were compared. Cells were plated onto 24-well plates at about 30-80% confluence, and then infected with Ad-DE1, YKL-1, YKL-GB or Ad-XC Ad at MOIs 1-100. Their killing effect was monitored daily under a microscope. At the moment that cells infected with any one of the virus exhibited complete cell lysis at low MOI, the dead cells were washed out, and cells on the plate were then stained with 0.5% crystal violet in 50% methanol.
Animal studies
All mice were maintained in a laminar airflow cabinet under specific pathogen-free conditions. All facilities are approved by AAALAC (Association of Assessment and Accreditation of Laboratory Animal Care), and all animal experiments were conducted under the institutional guidelines established for the Animal Core Facility at Yonsei University College of Medicine.
In vivo antitumor effect B16-F10 murine melanoma cells (5 Â 10 5 cells; syngeneic to C57BL/6 mice) in 100 ml Hank's balanced salt solution were injected into the abdominal area of 6-to 8-week-old male C57BL/6 mice. Tumor growth was monitored at 2-to 3-day intervals by measuring the length and width of the tumor with a caliper and calculating tumor volume on the basis of the following formula: volume ¼ 0.523Lw 2 . When tumors were in the range of 60-70 mm 3 in volume,
Oncolytic adenovirus-expressing GM-CSF and B7-1 K-J Choi et al PBS or Ads (dl-GB, YKL-1, YKL-GB) mixed with lipofectamin and plus solution (Gibco BRL) at a 2:6 ratio were administered intratumorally (5 Â 10 8 PFU per tumor in 50 ml of PBS) five times once every other day. The percentage of surviving mice was determined by monitoring the tumor growth-related events (tumor size42000 mm 3 ) over a period of 70 days. Survival curve was plotted against time after treatment (KaplanMeier survival function) and compared using a log-rank test analysis (StatView software; Abacus Concepts Inc., Berkeley, CA, USA). Differences in survival were considered statistically significant when P-values were o0.05.
Measurement of granulocyte-macrophage colonystimulating factor and interferon-g expression in tumor tissue
Tumor tissue was removed from mice treated with PBS, YKL-1 or YKL-GB and snap-frozen in liquid nitrogen. Tissues were homogenized and treated with protein inhibitor cocktail (Sigma). Homogenates were centrifuged in a high-speed microcentrifuge for 10 min and analyzed for total protein content using a BCA protein assay reagent kit (Bio-Rad, Hercules, CA, USA). Levels of GM-CSF and IFN-g in the supernatant were determined by ELISA (Endogen). Cytokine results were normalized relative to the total protein concentration in each tumor and were calculated as picograms per milligram of total protein.
Fluorescence-activated cell sorting analysis of spleen cells
For the assessment of T-cell and DC population, spleens were harvested 5 days after last viral injection into the B16-F10 tumor-bearing mice. Spleens were minced into single-cell suspensions in PBS plus 2% FCS, and treated with EDTA-ammonium chloride solution (0.15 M NH 4 Cl, 1 mM KHCO 3 , 0.1 mM EDTA) to remove red blood cells. Aliquots of 1 Â 10 6 cells were then stained with the following antibodies: fluorescein isothiocyanateconjugated anti-CD3e monoclonal antibody (145-2C11; DiNonA, Seoul, Korea), PE-conjugated anti-CD4/L3T4 monoclonal antibody (GK1.5; DiNonA) or PE-conjugated anti-CD8/Lyt-2 monoclonal antibody (53-6.7; DiNonA). For the assessment of DC population, splenocytes were stained with anti-CD11b (3A33; Southern Biotech, Birmingham, AL, USA), anti-CD80 (RMMP-1; Serotec, Oxford, UK) or anti-CD86 (GL-1; Southern Biotech) as a primary antibody, and goat anti-rat IgG-PE (catalog # 3050-09; Southern Biotech) as a secondary antibody. Cells were then fixed with 1% paraformaldehyde in PBS for fluorescence-activated cell sorting (FACS) analysis.
Interferon-g enzyme-linked immune spot assay
Enzyme-linked immune spot plates (Millipore, Bedford, MA, USA) were coated with Ab to murine IFN-g at 41C overnight. Splenocytes were then serially diluted from 1 Â 10 5 to 1 Â 10 6 cells per well and added into a 200 ml ELISPOT medium. After 24 h of incubation, plates were treated with biotinylated anti-IFN-g antibody for 2 h and then with streptavidin horseradish peroxidase (Pharmingen) for 1 h. Spots were developed by a 3-amino-9-ethylcarbazole (AEC) conjugate substrate (Pharmingen). The number of spots, corresponding to IFN-g-secreting cells, was determined with a KS-ELISPOT (Zeiss-Kontron).
Histology and immunohistochemistry
Tumor tissues for histological examination were fixed in 10% neutral buffered formalin, processed to paraffin embedment and cut into 4-mm sections. Representative sections were stained with H&E and examined by light microscopy. For the detection of Ad particles, slides were deparaffinized in xylene and then hydrated through graded alcohols. Endogenous peroxidase activity in the sections was blocked with 3% hydrogen peroxide. The primary mouse anti-Ad antibody, MAB8052 (Chemicon, Temecula, CA, USA), was first complexed with a biotinylated anti-mouse secondary antibody (Dako, Carpinteria, CA, USA). Mouse serum was added to the complexed primary and secondary antibodies to minimize potential interaction between uncomplexed secondary antibody and mouse immunoglobulin in the tissue section. The antibody complex was then applied to the sections and subsequently incubated with streptavdin-peroxidase. Diaminobenzidine/hydrogen peroxidase (DAKO) was used as the chromogen substrate. For the detection of lymphocytes and DC, tumor tissues were frozen in OCT compound (Sakura Finetec, Torrance, CA, USA), and cut into 10-mm sections. The cyrosections were treated with purified rat anti-mouse CD4 monoclonal antibody (Pharmingen), purified rat anti-mouse CD8 monoclonal antibody (Pharmingen) or purified rat anti-mouse CD86 monoclonal antibody (Pharmingen) as a primary antibody, and then with biotin-conjugated goat anti-rat IgG (Pharmingen) as a secondary antibody. Diaminobenzidine/hydrogen peroxidase (DAKO) was used as the chromogen substrate. All slides were counterstained with Meyer's hematoxylin.
Statistical analysis
The data were expressed as mean7standard error of the mean (s.e.m.). Statistical comparison was made using Stat View software (Abacus Concepts Inc., Berkeley, CA, USA) and the Mann-Whitney test (nonparametric method). The criterion for statistical significance was taken as Po0.05.
